A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta

Calcified Tissue International

Volumn 69, Issue 2, 2001, Pages 94-101

  Camacho, N P ^a   Raggio, C L ^a   Doty, S B ^a   Root, L ^a   Zraick, V ^a   Ilg, W A ^a   Toledano, T R ^a   Boskey, A L ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Bisphosphonates; Bone; Collagen; Mice; Mineralization; Osteogenesis imperfecta

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERALIZATION; CONTROLLED STUDY; FRACTURE; METAPHYSIS; MOUSE; NONHUMAN; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL;

NON-PROGRAMMATIC;

ALENDRONATE; ANIMALS; BONE AND BONES; BONE DEVELOPMENT; COLLAGEN; DISEASE MODELS, ANIMAL; FRACTURES, BONE; MICE; MICE, MUTANT STRAINS; OSTEOGENESIS IMPERFECTA;

EID: 0034892837     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002230010045     Document Type: Article

References (28)

1. Osteogenesis imperfecta
2. Osteogenesis imperfecta
3. New approaches to treatment of osteogenesis imperfecta
4. Heterozygous oim mice exhibit a mild form of osteogenesis imperfecta
5. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta
6. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta
7. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age
8. 2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats
9. Osteopetrosis
10. Sclerosing bone disorders
11. Osteogenesis imperfecta - Managing brittle bones
12. Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: A model of human osteogenesis imperfecta
13. Mutations in fibrillar collagens (types I, II, III, and XI), fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels
14. Confirmation of a G nucleotide deletion in the Cola-2 gene of mice with the osteogenesis imperfecta mutation
15. Identification of the oim mutation by dye terminator chemistry combined with automated direct DNA sequencing
16. Evaluation of alendronate for treatment in an animal model of osteogenesis imperfecta
17. Method of histomorphometric assessment of glycosaminoglycans in articular cartilage
18. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
19. Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis
20. Alendronate in the treatment of osteoporosis: A review of the clinical trials
21. Long-term effects of clodronate on growing rat bone
22. Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: Comparison with pamidronate and etidronate in growing rats
23. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones
24. Bisphosphonates: A review of their pharmacokinetic properties
25. Mechanisms of action of bisphosphonates: Information from animal models
26. Effects of large doses of olpadronate (dimethyl-pamidronate) on mineral density, cross-sectional architecture, and mechanical properties of rat femurs